News

The Phase 3 clinical trial of oral sebetralstat as an on-demand treatment for swelling attacks in people with hereditary angioedema (HAE) has reached its target enrollment of 114 patients. Findings from the global KONFIDENT study (NCT05259917) are expected by year’s end, according to the therapy’s developer,…

Firazyr (icatibant injection) rapidly eased acute attack symptoms in two Japanese children with hereditary angioedema (HAE), according to a study led by Takeda Pharmaceuticals, its developer. The therapy’s safety and pharmacological profile was also consistent with previous observations of adults and other pediatric patients. Firazyr’s approval in…

A woman still doesn’t have a definitive answer as to the underlying cause of her angioedema after more than a decade of recurrent facial swelling, underscoring the difficulties in diagnosing the condition. “This case report demonstrates the challenge of the differential diagnosis of angioedema without wheals,” the researchers wrote…

The U.S. Food and Drug Administration (FDA) has lifted its hold on clinical trials of deucrictibant for the on-demand treatment of hereditary angioedema (HAE). The therapy’s developer Pharvaris now expects to resume RAPIDe-2 (NCT05396105), a long-term extension study evaluating PHVS416, an immediate-release capsule formulation of deucrictibant,…

People with hereditary angioedema (HAE) tend to experience fewer emergency room visits and hospitalizations after starting treatment with Haegarda or Takhzyro (lanadelumab), a new analysis indicates. Despite the decreasing rates, some patients still experience health emergencies while on these therapies, which researchers said highlights the burden of…

On-demand treatment with the experimental oral therapy PHVS416 was found to quickly and effectively ease symptoms of swelling attacks for people with hereditary angioedema (HAE) in a Phase 2 clinical trial. PHVS416 worked within hours of dosing, providing “clinical meaningful” reductions in swelling symptoms, according to researchers. Pharvaris,…

Over the months after a single treatment with the experimental gene-editing therapy NTLA-2002, nine of 10 people with hereditary angioedema (HAE) in a Phase 1/2 trial have been free from swelling attacks. Three patients with high pretreatment attack rates, ranging from 4.4 to 16.8 each month, have gone without…

Birth control pills can induce life-threatening swelling attacks in people with hereditary angioedema (HAE), according to a case report. “We highlight the importance of obtaining a thorough family history regarding any HAE attack before initiation of [oral contraceptives], as this care may be lifesaving,” researchers wrote. The report, “…

The use of long-term preventive treatment among people with hereditary angioedema (HAE) was found to significantly reduce the rate of swelling attacks for patients in six countries, according to a new study conducted in North America, Europe, and Australia. Considering the effectiveness of long-term prophylaxis in preventing HAE attacks,…

Ionis Pharmaceuticals has finished enrollment in a Phase 3 clinical trial testing the ability of its experimental therapy donidalorsen to prevent swelling attacks in people with hereditary angioedema (HAE) types 1 or 2. Results from the placebo-controlled study, dubbed OASIS-HAE (NCT05139810), are expected in the first half…